Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04534465 · ClinicalTrials.gov registry record · Phase 4
Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.
A Phase 4 study of Constipation, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04534465 is a Phase 4 study of Constipation that has completed, run by Bayer. The registered enrollment target is 50 participants, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04534465, a Phase 4 study of Constipation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of the sugar alcohol Mannitol for Polyethylene glycol (PEG) 3350 a drug stimulating bowel movement to pass stool in subjects having infrequent bowel movements. The taste of the various preparations will be measured by use of a rating scale.
Conditions Studied
Interventions
- DRUG Polyethylene glycol (MiraLAX, BAY81-8430)
- DRUG Mannitol
Study Locations (1)
Tennessee
- Merck Consumer Center - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-02-13 |
| Est. Completion | 2013-03-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04534465
The ClinicalTrials.gov registry entry for NCT04534465 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 54 other Constipation trials with a reported enrollment target (75% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Constipation appearing as the primary indexed condition, and to 2 interventions - of which Polyethylene glycol (MiraLAX, BAY81-8430) is the first listed.
NCT04534465 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT04534465 about?
NCT04534465 is a clinical study titled "Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.". Study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of the sugar alcohol Mannitol for Polyethylene glycol (PEG) 3350 a drug stimulating bowel movement to pass stool in subjects having infrequent bowel movements. The taste of the vario...
What is the current status of trial NCT04534465?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2013-02-13. Estimated completion is 2013-03-19.
What conditions does trial NCT04534465 study?
This clinical trial studies the following conditions: Constipation.
What interventions are being tested in trial NCT04534465?
The interventions under investigation include: Polyethylene glycol (MiraLAX, BAY81-8430) (DRUG), Mannitol (DRUG).
Who is sponsoring clinical trial NCT04534465?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04534465 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery
RECRUITING · Phase 4
-
Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
COMPLETED · Phase 4
-
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
COMPLETED · Phase 4
-
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.